Hologic, Inc. (NASDAQ:HOLX) Shares Sold by AlphaQuest LLC

AlphaQuest LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 52.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,791 shares of the medical equipment provider’s stock after selling 24,048 shares during the quarter. AlphaQuest LLC’s holdings in Hologic were worth $1,571,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Hologic in the 4th quarter worth $27,007,000. Swedbank AB increased its stake in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after acquiring an additional 238,222 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of HOLX opened at $64.54 on Monday. The stock has a 50-day simple moving average of $68.19 and a 200-day simple moving average of $75.27. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a market capitalization of $14.48 billion, a PE ratio of 20.36, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1 year low of $61.70 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

HOLX has been the subject of a number of recent research reports. Morgan Stanley cut their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Royal Bank of Canada lowered their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Hologic currently has an average rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.